Research Themes

Patient recruitment & compliance in clinical trials, Clinical trials operational methodology



Dr Wendy Hague

Clinical Trials Strategic Development Director

Key attributes: strategic thinking, leadership, financial acumen, strong interest in management information systems, pragmatic and strive for efficiency and excellence in the face of major funding constraints.

Wendy is medically trained but has spent her career in clinical trials research, initially in the pharmaceutical industry and subsequently in academic clinical trials research where she has evolved both her research (PhD) and business/management/leadership skills (MBA, GAICD) to complement her clinical insight into specific clinical trial protocols.

Wendy joined the CTC in 1990 as the LIPD Study Manager, the first major phase III cardiovascular study developed and coordinated by the CTC. In 2000 she established the role of Clinical Trials Program Director which she undertook for 18 years, where among other things, she established trial functional teams to support the ever growing trial project teams, oversaw the establishment of electronic data capture, established protocol and budget templates, project plans and standardised reports for metrics and milestones. She did all of this with a major focus on the establishment of major Phase III locally led international trial initiatives.

Wendy is currently the Director of Clinical Trials Strategic Development Initiatives, another new role, which is evolving over time. She is reviewing current CTC systems for finance and trial metrics with a view to standardising reporting across the CTC so data can be shared via a comprehensive organisation dashboard with role/function and program based views.

Wendy also maintains her academic interests via publications, TMC and some external committee membership. Some of her notable publications relating to major/pivotal studies led by the CTC include:

  1. T4DM – TBA - main results submitted for publication.
  2. Davis ID ……Hague W……. Sweeny CJ, .Enzalutamide with standard first-line therapy in metastatic prostate cancer. NEJM 2019381;2:121-131 (primary results)
  3. Hague WE, et al. Long-term effectiveness and safety of pravastatin in patients with coronary heart disease: 16 years of follow-up of the LIPID Study. Circulation 2016; 133: 1851–60.
  4. Tarnow-Mordi W, … Hague W, … Outcomes of two trials of oxygen-saturation targets in preterm infants. N Engl J Med 2016; 374: 749–60.
  5. Stevenson AR… Hague W, … Effect of laparoscopic-assisted resection vs open resection on pathological outcomes in rectal cancer: the ALaCaRT randomized clinical trial. JAMA 2015; 314(13): 1356–63.
  6. Stenson BJ, … Hague W, … Oxygen saturation and outcomes in preterm infants. N Engl J Med 2013; 368: 2094–104.
  7. Brighton T, … Hague W, … Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med 2012; 367: 1979–87.
  8. Hague, W.E (PhD). Identification of Determinants of Patient Compliance in Placebo-controlled Clinical Trials and Appropriate Strategies to Improve Study Compliance – the LIPID Study, University of Sydney, 2004.

View Wendy's other publications.